Access Bio Inc
950130.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$224.58B
Close$
Share Statistics
| Market cap | $224.58 Billion |
|---|---|
| Enterprise Value | $-41,910,115,000.00 |
| Dividend Yield | $871.00 (-) |
| Earnings per Share | $-9.9 |
| Beta | 1 |
| Outstanding Shares | 35,145,000 |
Return
| Return on Equity | -3.64% |
|---|---|
| Return on Assets | -3.26% |
| Return on Invested Capital | -4.03% |
Valuation & Multiples
| P/E Ratio | -645.45 |
|---|---|
| PEG | 81.67 |
| Price to Sales | 3.01 |
| Price to Book Ratio | 0.37 |
| Enterprise Value to Revenue | -2.51 |
| Enterprise Value to EBIT | 7.3 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | -0.32 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Access Bio, Inc.
130 employees
CEO: Young-Ho Choi Access Bio, Inc. engages in the research, development, and manufacture of in-vitro diagnostic tests, immunochemical diagnosis, biosensor, and molecular diagnostic technology. Its products are diagnostic reagents that diagnose infectious ...